Literature DB >> 26677434

Direct therapeutic intervention for advanced pancreatic cancer.

Kazuki Takakura1, Shigeo Koido1.   

Abstract

Currently, chemotherapy is an accredited, standard treatment for unresectable, advanced pancreatic cancer (PC). However, it has been still showed treatment-resistance and followed dismal prognosis in many cases. Therefore, some sort of new, additional treatments are needed for the better therapeutic results for advanced PC. According to the previous reports, it is obvious that interventional endoscopic ultrasonography (EUS) is a well-established, helpful and low-risky procedure in general. As the additional treatments of the conventional therapy for advanced PC, many therapeutic strategies, such as immunotherapies, molecular biological therapies, physiochemical therapies, radioactive therapies, using siRNA, using autophagy have been developing in recent years. Moreover, the efficacy of the other potential therapeutic targets for PC using EUS-fine needle injection, for example, intra-tumoral chemotherapeutic agents (paclitaxel, irinotecan), several ablative energies (radiofrequency ablation and cryothermal treatment, neodymium-doped yttrium aluminum garnet laser, high-intensity focused ultrasound), etc., has already been showed in animal models. Delivering these promising treatments reliably inside tumor, interventional EUS may probably be indispensable existence for the treatment of locally advanced PC in near future.

Entities:  

Keywords:  Advanced pancreatic cancer; Dendritic cells; Endoscopic ultrasonography guided-fine needle injection; Gemcitabine; Interventional endoscopic ultrasonography; Radiofrequency ablation

Year:  2015        PMID: 26677434      PMCID: PMC4675906          DOI: 10.5306/wjco.v6.i6.216

Source DB:  PubMed          Journal:  World J Clin Oncol        ISSN: 2218-4333


  17 in total

1.  EUS-guided photodynamic therapy of the pancreas: a pilot study.

Authors:  Hoi-Hung Chan; Norman Shizuaki Nishioka; Mari Mino; Gregory Yves Lauwers; William Peter Puricelli; Kerry Naomi Collier; William Robert Brugge
Journal:  Gastrointest Endosc       Date:  2004-01       Impact factor: 9.427

Review 2.  The dendritic cell system and its role in immunogenicity.

Authors:  R M Steinman
Journal:  Annu Rev Immunol       Date:  1991       Impact factor: 28.527

3.  EUS-guided injection of paclitaxel (OncoGel) provides therapeutic drug concentrations in the porcine pancreas (with video).

Authors:  Kai Matthes; Mari Mino-Kenudson; Dushyant V Sahani; Nagaraj Holalkere; Kirk D Fowers; Ramesh Rathi; William R Brugge
Journal:  Gastrointest Endosc       Date:  2006-12-14       Impact factor: 9.427

4.  Endoscopic ultrasound-guided interstitial brachytherapy of unresectable pancreatic cancer: results of a pilot trial.

Authors:  S Sun; H Xu; J Xin; J Liu; Q Guo; S Li
Journal:  Endoscopy       Date:  2006-04       Impact factor: 10.093

5.  EUS-guided Nd:YAG laser ablation of normal pancreatic tissue: a pilot study in a pig model.

Authors:  Francesco Di Matteo; Margareth Martino; Roberta Rea; Monica Pandolfi; Carla Rabitti; Grazia Maria Paola Masselli; Sergio Silvestri; Claudio Maurizio Pacella; Enrico Papini; Francesco Panzera; Sergio Valeri; Roberto Coppola; Guido Costamagna
Journal:  Gastrointest Endosc       Date:  2010-06-11       Impact factor: 9.427

6.  Phase I clinical trial of allogeneic mixed lymphocyte culture (cytoimplant) delivered by endoscopic ultrasound-guided fine-needle injection in patients with advanced pancreatic carcinoma.

Authors:  K J Chang; P T Nguyen; J A Thompson; T T Kurosaki; L R Casey; E C Leung; G A Granger
Journal:  Cancer       Date:  2000-03-15       Impact factor: 6.860

7.  A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma.

Authors:  J Randolph Hecht; Rudolph Bedford; James L Abbruzzese; Sandeep Lahoti; Tony R Reid; Roy M Soetikno; David H Kirn; Scott M Freeman
Journal:  Clin Cancer Res       Date:  2003-02       Impact factor: 12.531

8.  TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors.

Authors:  Neil Senzer; Sridhar Mani; Alexander Rosemurgy; John Nemunaitis; Casey Cunningham; Chandan Guha; Natalia Bayol; Michelle Gillen; Karen Chu; Camilla Rasmussen; Henrik Rasmussen; Donald Kufe; Ralph Weichselbaum; Nader Hanna
Journal:  J Clin Oncol       Date:  2004-01-15       Impact factor: 44.544

9.  Preclinical in vivo evaluation of an extracorporeal HIFU device for ablation of pancreatic tumors.

Authors:  Joo Ha Hwang; Yak-Nam Wang; Cinderella Warren; Melissa P Upton; Frank Starr; Yufeng Zhou; Stuart B Mitchell
Journal:  Ultrasound Med Biol       Date:  2009-02-08       Impact factor: 2.998

10.  Elucidation of the molecular mechanism underlying tumor-selective replication of the oncolytic adenovirus mutant ONYX-015.

Authors:  Stefan J Ries
Journal:  Future Oncol       Date:  2005-12       Impact factor: 3.404

View more
  2 in total

Review 1.  Focused ultrasound: tumour ablation and its potential to enhance immunological therapy to cancer.

Authors:  Giovanni Mauri; Luca Nicosia; Zhen Xu; Salvatore Di Pietro; Lorenzo Monfardini; Guido Bonomo; Gianluca Maria Varano; Francesco Prada; Paolo Della Vigna; Franco Orsi
Journal:  Br J Radiol       Date:  2018-01-17       Impact factor: 3.039

2.  Novel Use of Hypoxia-Inducible Polymerizable Protein to Augment Chemotherapy for Pancreatic Cancer.

Authors:  Andrew Gdowski; Hamed Hayatshahi; Rafal Fudala; Rohan Joshi; Jin Liu; Jamboor K Vishwanatha; Rohan Jeyarajah; Paul Guzik; Amalendu P Ranjan
Journal:  Pharmaceutics       Date:  2022-01-05       Impact factor: 6.321

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.